|
|
Article: AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction.
- Article from:
- PR Newswire
- Article date:
- July 7, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences
QUEBEC CITY, July 7 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication in the renowned American scientific journal, Proceedings of the National Academy of Sciences (PNAS), of new data supporting the use of AEterna Zentaris' ghrelin receptor antagonist compound, AEZS-123 (JMV2959), for the treatment of alcohol dependence that involves ghrelin. Ghrelin is a hormone produced by the stomach and acting in the brain. Compelling evidence obtained with the ...